全文获取类型
收费全文 | 692篇 |
免费 | 21篇 |
国内免费 | 35篇 |
出版年
2023年 | 1篇 |
2022年 | 1篇 |
2021年 | 5篇 |
2020年 | 8篇 |
2019年 | 12篇 |
2018年 | 16篇 |
2017年 | 6篇 |
2016年 | 11篇 |
2015年 | 15篇 |
2014年 | 23篇 |
2013年 | 27篇 |
2012年 | 33篇 |
2011年 | 26篇 |
2010年 | 26篇 |
2009年 | 27篇 |
2008年 | 32篇 |
2007年 | 61篇 |
2006年 | 38篇 |
2005年 | 57篇 |
2004年 | 26篇 |
2003年 | 22篇 |
2002年 | 29篇 |
2001年 | 13篇 |
2000年 | 16篇 |
1999年 | 27篇 |
1998年 | 14篇 |
1997年 | 28篇 |
1996年 | 18篇 |
1995年 | 19篇 |
1994年 | 11篇 |
1993年 | 20篇 |
1992年 | 18篇 |
1991年 | 12篇 |
1990年 | 19篇 |
1989年 | 19篇 |
1988年 | 4篇 |
1987年 | 2篇 |
1986年 | 2篇 |
1985年 | 2篇 |
1984年 | 2篇 |
排序方式: 共有748条查询结果,搜索用时 406 毫秒
101.
Bourinbaiar AS Borkowsky W Krasinski KM Fruhstorfer EC 《Journal of biomedical science》1997,4(4):162-168
Although placental trophoblasts, the only fetal cells in direct contact with infectious maternal blood, can be infected with HIV, the precise cause for the low transmission rate of virus across the placental barrier is unknown. One of the most common conjectures is that maternal anti-HIV antibodies (Abs) contribute to the protection of the fetus. This hypothesis has been tested in vitro by infecting the CD4-negative placental trophoblast line, BeWo, with HIV-1IIIB in the presence of serial dilutions of neutralizing monoclonal Abs against the V3 loop (No. 694) or CD4-binding conformational domain (No. 588). The results, based on measurement of p24 production from virus-exposed cells, reveal that the titers of Abs, adequate in preventing the infection of control MT-4 T lymphocytes, were less effective in protecting trophoblasts. Furthermore, PCR analysis of HIV DNA formed after a single round of infection has shown no significant decrease in the number of viral copies in Ab-protected BeWo cells. An anti-HIV serum from a pregnant woman did also have no effect. Although our in vitro observations do not necessarily apply to the in vivo situation, the results suggest that the humoral immune response sustained by neutralizing Abs may be able to protect T lymphocytes, but not placental trophoblasts. The findings are consistent with recent clinical studies demonstrating a lack of correlation between the presence of neutralizing anti-HIV Abs in pregnant women and HIV transmission in utero. 相似文献
102.
用猴艾滋病D型逆转录病毒筛选抗艾滋病药物实验模型的建立及应用 总被引:3,自引:0,他引:3
以药物对合胞体形成的抑制和对细胞的毒性作为检测指标,应用猴艾滋病D型逆转录病毒(SRV)/Raji细胞系统建立了体外筛选抗艾滋病药物的实验模型。AZT和天花粉蛋白可显著地抑制SRV诱导的合胞体形成,它们的选择指数(SI)分别为数13500和8812。用该模型筛选了46种来源于天然资源的化合物,结果表明有11种天然化合物有明显的抗病毒活性。 相似文献
103.
Toxoplasmosis, a neglected tropical disease caused by the protozoan parasite Toxoplasma gondii, occurs throughout the world. Human T. gondii infection is asymptomatic in 80% of the population; however, the infection is life-threatening and causes substantial neurologic damage in immunocompromised patients such as HIV-infected persons. The major purpose of this study was to investigate the seroprevalence of T. gondii infection in subjects infected with HIV/AIDS in eastern China. Our findings showed 9.7% prevalence of anti-T. gondii IgG antibody in HIV/AIDS patients, which was higher than in intravenous drug users (2.2%) and healthy controls (4.7%), while no significant difference was observed in the seroprevalence of anti-Toxoplasma IgM antibody among all participants (P>0.05). Among all HIV/AIDS patients, 15 men (7.7%) and 10 women (15.9%) were positive for anti-T. gondii IgG antibody; however, no significant difference was detected in the seroprevalence of anti-Toxoplasma IgG antibody between males and females. The frequency of anti-Toxoplasma IgG antibody was 8.0%, 13.2%, 5.5%, and 0% in patients with normal immune function (CD4+ T-lymphocyte count ≥500 cells/ml), immunocompromised patients (cell count ≥200 and <500 cells/ml), severely immunocompromised patients (cell count ≥50 and <200 cells/ml), and advanced AIDS patients, respectively (cell count <50 cells/ml), while only 3 immunocompromised patients were positive for anti-T. gondii IgM antibody. The results indicate a high seroprevalence of T. gondii infection in HIV/AIDS patients in eastern China, and a preventive therapy for toxoplasmosis may be given to HIV/AIDS patients based on CD4+ T lymphocyte count. 相似文献
104.
小鼠艾滋病模型的建立及用鹿肠道病毒治疗的实验研究 总被引:1,自引:0,他引:1
用小鼠白血病病毒LP-BM5MuLV接种新生BALB/C小鼠,感染后4~6个月可出现与人类AIDS极为相似的病理变化和免疫缺陷的症状,包括血免疫球蛋白增高、淋巴结肿大、T辅助淋巴细胞减少和淋巴细胞转化功能降低等。通常作为小鼠获得性免疫缺陷综合症即小鼠艾滋病(MAIDS)的模型使用。本实验采用已证实具有溶瘤作用的鹿肠道病毒ECCO-18株对小鼠艾滋病进行实验性治疗,结果表明鹿肠道病毒ECCO-18可明显缓解艾滋病小鼠的淋巴结肿大和延长艾滋病小鼠的生存时间。提示鹿肠道病毒ECCO-18治疗小鼠艾滋病有效。 相似文献
105.
Michael Haber 《Biometrical journal. Biometrische Zeitschrift》1999,41(5):533-542
Longini , Datta , and Halloran (1996) proposed to design HIV vaccine trials in a way that will permit the simultaneous estimation of the vaccine effects on susceptibility to infection and on infectiousness of vaccine brak-throughs. The main feature of their design is the inclusion of steady partners of trial participants. They estimate four parameters from the vaccine trial: the probability that a susceptible person will become infected from his/her steady partner, the probability of becoming infected from outside the partnership, the vaccine efficacy for susceptibility and the vaccine efficacy for infectiousness. We show how the estimates of these parameters can be used to predict the attack rate in a given population during a specified period following mass-vaccination. This is an iterative method, as the attack rate depends on the HIV prevalence which, in turn, depends on the number of new cases during that period. The same method is also used to estimate the attack rate in that population during the same period in the absence of vaccination. The estimated attack rates allow us to estimate the population vaccination effectiveness, defined as the fraction HIV cases prevented by a vaccination program. 相似文献
106.
Lyudmila G. Nikolaeva Tatiana V. Maystat Volodymyr S. Pylypchuk Yuri L. Volyanskii Valery M. Frolov Galyna A. Kutsyna 《Cytokine》2008,44(3):392-396
Dzherelo (Immunoxel) and Anemin when combined with standard anti-tuberculosis therapy (ATT) were shown to produce better clinical outcome than chemotherapy alone. Sixty HIV-positive patients with active pulmonary TB were equally divided into three matched groups to receive either ATT, ATT + Dzherelo, or ATT + Dzherelo + Anemin. Peripheral blood samples were measured by ELISA for plasma levels of IL-2, IL-6, TNF-α, IFN-γ, and IFN-α. After 6 months of follow-up Dzherelo and Dzherelo + Anemin combinations produced 61% (P = 0.005) and 44.4% (P = 0.06) higher levels of IL-2, whereas in ATT group they were reduced by 33.1% (P = 0.002). The levels of IL-6 increased by 17% (P = 0.15) in ATT group, but declined in both immune intervention groups by 26.2% (P = 0.007) and 21.3% (P = 0.22). TNF-α was suppressed in two immunotherapy groups by 19.1% (P = 0.06) and 76.3% (P = 0.02), respectively, but had risen by 14% (P = 0.42) in ATT patients. The pattern of production of IFN-γ was opposite to that of TNF-α, but statistical significance was stronger in patients receiving ATT and Dzherelo + Anemin than in Dzherelo group: −34% (P = 0.004), +31.9% (P = 0.008), and +17.3% (P = 0.33), respectively. Moderately decreased levels of IFN-α were observed in all treatment arms (range 0.9–16.6%) but differences were not significant. Despite considerable intra-group variation in cytokine production, the baseline inter-group averages were not statistically different indicating that the results were not biased by sample heterogeneity. Immunomodulators used in this study possibly act by enhancing natural immune response against TB. Expanded study of other cytokines and correlates relevant to control and protection from TB and HIV is needed in order to identify biomarkers of favorable treatment outcome, which may aid design of better immune interventions and vaccines. 相似文献
107.
Since the introduction of drugs to prevent vertical transmission of HIV, the purpose of and approach to HIV testing of pregnant women has increasingly become an area of major controversy. In recent years, many strategies to increase the uptake of HIV testing have focused on offering HIV tests to women in pregnancy-related services. New global guidance issued by the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) specifically notes these services as an entry point for provider-initiated HIV testing and counseling (PITC). The guidance constitutes a useful first step towards a framework within which PITC sensitive to health, human rights and ethical concerns can be provided to pregnant women in health facilities. However, a number of issues will require further attention as implementation moves forward. It is incumbent on all those involved in the scale up of PITC to ensure that it promotes long-term connection with relevant health services and does not result simply in increased testing with no concrete benefits being accrued by the women being tested. Within health services, this will require significant attention to informed consent, pre- and post-test counseling, patient confidentiality, referrals and access to appropriate services, as well as reduction of stigma and discrimination. Beyond health services, efforts will be needed to address larger societal, legal, policy and contextual issues. The health and human rights of pregnant women must be a primary consideration in how HIV testing is implemented; they can benefit greatly from PITC but only if it is carried out appropriately. 相似文献
108.
Christine Neuveut Robert M. Scoggins David Camerini Richard B. Markham Kuan-Teh Jeang 《Journal of biomedical science》2003,10(6):651-660
HIV-1 Tat is essential for virus replication and is a potent transactivator of viral gene expression. Evidence suggests that Tat also influences virus infectivity and cytopathicity. Here, we find that the second coding exon of Tat contributes a novel function for the replication/infectivity of macrophage-tropic HIV-1. We show that macrophage-tropic HIV-1 which expresses the full-length two-exon form of Tat replicates better in monocyte-derived macrophages (MDM) than an otherwise isogenic virus which expresses only the one-exon form of Tat. Similarly, two-exon Tat expressing HIV-1 also replicates better than one-exon Tat expressing HIV-1 in two different models of human cells/tissue reconstituted SCID mice. 相似文献
109.
通过检测74例处于不同病期的HIV感染者/AIDS患者和10例健康对照者PBMCs中HMGB1 mRNA的表达水平及其外周血浆HMGB1、TNF-a和IL-2水平,比较各组之间表达水平的差异及其与CD4+T淋巴细胞的关系.发现HMGB1 mRNA的表达水平及血浆HMGB1含量在AIDS病人组明显高于感染者组和正常对照组(P〈0.05);AIDS患者经HAART治疗后疗效差组HMGB1 mRNA的表达水平及血浆HMGB1含量也明显高于疗效好组(P〈0.05);而经HAART治疗后效果好且免疫功能恢复的患者HMGB1 mRNA的表达及血浆HMGB1含量均较治疗前明显下降(P〈0.05);当CD4+T细胞数低于200/μL时,血浆HMGB1含量以及PBMCs中HMGB1 mRNA表达水平与CD4+T细胞数呈负相关.显示HMGB1在HIV/AIDS发病及病情进展过程中可能起重要作用,HMGB1血浆含量及PBMCs中HMGB1 mRNA的表达水平高低与HIV/AIDS患者病情轻重密切相关. 相似文献
110.
Edward T. Mee Neil Berry Claire Ham Ulrike Sauermann Maria T. Maggiorella Frédéric Martinon Ernst J. Verschoor Jonathan L. Heeney Roger Le Grand Fausto Titti Neil Almond Nicola J. Rose 《Immunogenetics》2009,61(5):327-339
The restricted diversity of the major histocompatibility complex (MHC) of Mauritian cynomolgus macaques provides powerful
opportunities for insight into host-viral interactions and cellular immune responses that restrict lentiviral infections.
However, little is known about the effects of Mhc haplotypes on control of SIV in this species. Using microsatellite-based
genotyping and allele-specific PCR, Mhc haplotypes were deduced for 35 macaques infected with the same stock of SIVmac251.
Class I haplotype H6 was associated with a reduction in chronic phase viraemia (p = 0.0145) while a similar association was observed for H6 class II (p = 0.0063). An increase in chronic phase viraemia, albeit an insignificant trend, was observed in haplotype H5-positive animals.
These results further emphasise the value of genetically defined populations of non-human primates in AIDS research and provide
a foundation for detailed characterisation of MHC restricted cellular immune responses and the effects of host genetics on
SIV replication in cynomolgus macaques.
Electronic supplementary material The online version of this article (doi:) contains supplementary material, which is available to authorized users. 相似文献